Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTP2NJ)

• Drug Name: Desonide Drug Info
• Synonyms: Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Atopic dermatitis	EA80	Approved	[2]
Crohn disease	DD70	Approved	[1]
Exanthem		Approved	[1]
Granuloma annulare		Approved	[1]
Primary cutaneous T-cell lymphoma		Approved	[1]
Asthma	CA23	Investigative	[1]

• Therapeutic Class: Antiinflammatory Agents
• Cross-matching ID:
  PubChem CID: 5311066
  ChEBI ID: CHEBI:204734
  CAS Number: CAS 638-94-8
  TTD Drug ID: DMTP2NJ
  INTEDE Drug ID: DR0439
  ACDINA Drug ID: D00997

Molecule-Related Drug Atlas

Drug(s) Targeting Steroid hormone receptor ERR (ESRR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cortisone Acetate	DMG8K57	Acne vulgaris	ED80	Approved	[3]
Beclomethasone	DMZPHIK	Allergic rhinitis	CA08.0	Approved	[3]
Auranofin	DMWE2N4	Inflammatory arthritis	FA2Z	Approved	[3]
Loteprednol Etabonate	DM8QTJI	Eye inflammation	9A02	Approved	[3]
Fluocinonide	DM65KL8	Exanthem		Approved	[3]
Medrysone	DMJ90O5	Corneal abrasion	NA06.4	Approved	[3]
Halcinonide	DMGLAX1	Exanthem		Approved	[3]
Amcinonide	DMM1JL9	Exanthem		Approved	[3]
Prednicarbate	DMBUNVW	Exanthem		Approved	[3]
Flurandrenolide	DMHCI9S	Exanthem		Approved	[3]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[5]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[6]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[7]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[8]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[9]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[11]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[12]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[6]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Steroid hormone receptor ERR (ESRR)	TTP3UTW	ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[4]

References

• [1] Desonide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7066).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [5] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [6] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [7] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [8] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [9] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [10] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [11] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [12] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [13] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.